Legal OutcomeThe U.S. Court of Appeals for the Federal Circuit upheld the District Court's rulings around Xifaxan, barring Norwich's generic application until 2029, eliminating the risk of imminent Xifaxan generic competition.
Market SentimentBHC shares have traded 30% higher in anticipation of the court ruling, indicating strong market optimism.
Spin-Off ProbabilityWith the litigation hurdles cleared, there is an increased probability of a successful spin-off, which is expected to drive BHC shares higher.